Skip to main content
. 2023 Mar 6;10(1):e001508. doi: 10.1136/bmjresp-2022-001508

Figure 3.

Figure 3

Proportion of patients with individual pharmacotherapy prescriptions, and those grouped by SAMA/SABA, LAMA/LABA or+ICS. ICS, inhaled corticosteroid; LABA, long-acting β-agonist; LAMA, long-acting muscarinic antagonist; SABA, short-acting beta agonist; SAMA, short-acting muscarinic antagonist.